146 related articles for article (PubMed ID: 21823932)
1. Rapid and sustained resolution of serous retinal detachment in Sturge-Weber syndrome after single injection of intravitreal bevacizumab.
Shoeibi N; Ahmadieh H; Abrishami M; Poorzand H
Ocul Immunol Inflamm; 2011 Oct; 19(5):358-60. PubMed ID: 21823932
[TBL] [Abstract][Full Text] [Related]
2. Treatment of serous macular detachment associated with circumscribed choroidal hemangioma.
Kwon HJ; Kim M; Lee CS; Lee SC
Am J Ophthalmol; 2012 Jul; 154(1):137-145.e1. PubMed ID: 22465363
[TBL] [Abstract][Full Text] [Related]
3. [Recurrent and chronic central serous chorioretinopathy. Retina thickness evaluation one month after intravitreal bevacizumab injection].
Gregori-Gisbert I; Aguirre-Balsalobre F; García-Sánchez J; León-Salvatierra G; Mengual-Verdú E; Hueso-Abancéns JR
Arch Soc Esp Oftalmol; 2011 Dec; 86(12):407-11. PubMed ID: 22117740
[TBL] [Abstract][Full Text] [Related]
4. Diffuse choroidal hemangioma associated with exudative retinal detachment in a Sturge-Weber syndrome case: photodynamic therapy and intravitreous bevacizumab.
Anaya-Pava EJ; Saenz-Bocanegra CH; Flores-Trejo A; Castro-Santana NA
Photodiagnosis Photodyn Ther; 2015 Mar; 12(1):136-9. PubMed ID: 25560419
[TBL] [Abstract][Full Text] [Related]
5. Intravitreal bevacizumab in central serous chorioretinopathy.
Jamil AZ; Rahman FU; Iqbal K; Ansari HM; Iqbal W; Mirza KA
J Coll Physicians Surg Pak; 2012 Jun; 22(6):363-6. PubMed ID: 22630094
[TBL] [Abstract][Full Text] [Related]
6. The efficacy of intravitreal bevacizumab for acute central serous chorioretinopathy.
Aydin E
J Ocul Pharmacol Ther; 2013 Feb; 29(1):10-3. PubMed ID: 22925113
[TBL] [Abstract][Full Text] [Related]
7. Regression of serous macular detachment due to peripheral exudative hemorrhagic chorioretinopathy following intravitreal bevacizumab.
Barkmeier AJ; Kadikoy H; Holz ER; Carvounis PE
Eur J Ophthalmol; 2011; 21(4):506-8. PubMed ID: 21240857
[TBL] [Abstract][Full Text] [Related]
8. Intravitreal bevacizumab to treat acute central serous chorioretinopathy: short-term effect.
Seong HK; Bae JH; Kim ES; Han JR; Nam WH; Kim HK
Ophthalmologica; 2009; 223(5):343-7. PubMed ID: 19521133
[TBL] [Abstract][Full Text] [Related]
9. Intravitreal bevacizumab in treatment of idiopathic persistent central serous chorioretinopathy: a prospective, controlled clinical study.
Artunay O; Yuzbasioglu E; Rasier R; Sengul A; Bahcecioglu H
Curr Eye Res; 2010 Feb; 35(2):91-8. PubMed ID: 20136418
[TBL] [Abstract][Full Text] [Related]
10. Treatment of persistent serous retinal detachment in Vogt-Koyanagi-Harada syndrome with intravitreal bevacizumab during the systemic steroid treatment.
Reibaldi M; Russo A; Avitabile T; Uva MG; Franco L; Longo A; Toro MD; Cennamo G; Mariotti C; Neri P; Noci ND; Russo V
Retina; 2014 Mar; 34(3):490-6. PubMed ID: 23903795
[TBL] [Abstract][Full Text] [Related]
11. The treatment of recurrent central serous chorioretinopathy with intravitreal bevacizumab.
Lee ST; Adelman RA
J Ocul Pharmacol Ther; 2011 Dec; 27(6):611-4. PubMed ID: 21810026
[TBL] [Abstract][Full Text] [Related]
12. Intravitreal bevacizumab in the management of subretinal fluid associated with choroidal osteoma.
Song JH; Bae JH; Rho MI; Lee SC
Retina; 2010 Jun; 30(6):945-51. PubMed ID: 20531145
[TBL] [Abstract][Full Text] [Related]
13. [Patient with recurrent central serous chorioretinopathy who developed multiple evanescent white dots and serous retinal detachment immediately following bevacizumab administration].
Satoh S; Miyagawa Y; Mori T
Nippon Ganka Gakkai Zasshi; 2012 Feb; 116(2):119-28. PubMed ID: 22509701
[TBL] [Abstract][Full Text] [Related]
14. Intravitreal ranibizumab for acute central serous chorioretinopathy.
Kim M; Lee SC; Lee SJ
Ophthalmologica; 2013; 229(3):152-7. PubMed ID: 23257663
[TBL] [Abstract][Full Text] [Related]
15. Bilateral intravitreal bevacizumab injection for exudative age-related macular degeneration: effect of baseline visual acuity.
Jonas JB; Tao Y; Rensch F
J Ocul Pharmacol Ther; 2011 Aug; 27(4):401-5. PubMed ID: 21810019
[TBL] [Abstract][Full Text] [Related]
16. Intravitreal bevacizumab combined with photodynamic therapy for the treatment of occult choroidal neovascularization associated with serous pigment epithelium detachment in age-related macular degeneration.
Ladas ID; Kotsolis AI; Papakostas TD; Rouvas AA; Karagiannis DA; Vergados I
Retina; 2007 Sep; 27(7):891-6. PubMed ID: 17891013
[TBL] [Abstract][Full Text] [Related]
17. Effect of intravitreal bevacizumab based on optical coherence tomography patterns of diabetic macular edema.
Kim M; Lee P; Kim Y; Yu SY; Kwak HW
Ophthalmologica; 2011; 226(3):138-44. PubMed ID: 21822008
[TBL] [Abstract][Full Text] [Related]
18. Intravitreal bevacizumab injection for central serous chorioretinopathy.
Lim SJ; Roh MI; Kwon OW
Retina; 2010 Jan; 30(1):100-6. PubMed ID: 20010322
[TBL] [Abstract][Full Text] [Related]
19. Intravitreal bevacizumab in vascular pigment epithelium detachment as a result of subfoveal occult choroidal neovascularization in age-related macular degeneration.
Ach T; Hoeh AE; Ruppenstein M; Kretz FT; Dithmar S
Retina; 2010 Oct; 30(9):1420-5. PubMed ID: 20543764
[TBL] [Abstract][Full Text] [Related]
20. Intravitreal bevacizumab for treatment of subfoveal idiopathic choroidal neovascularization: results of a 1-year prospective trial.
Zhang H; Liu ZL; Sun P; Gu F
Am J Ophthalmol; 2012 Feb; 153(2):300-306.e1. PubMed ID: 21982109
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
